Lys366
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Mono-methylation Site Page: > Lys366  -  IRF3 (human)

Site Information
TKRLVMVkVVPtCLR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1873286920

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mass spectrometry ( 2 ) , modification-specific antibody ( 2 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 2 )
Relevant cell line - cell type - tissue:
HEK293T (epithelial) ( 2 ) , macrophage-peritoneum ( 2 ) , MEF (fibroblast) ( 2 ) , RAW 264.7 (macrophage) ( 2 )

Upstream Regulation
Treatments:
virus infection ( 1 , 2 )

Downstream Regulation
Effects of modification on IRF3:
molecular association, regulation ( 2 ) , phosphorylation ( 1 , 2 )
Effects of modification on biological processes:
transcription, induced ( 1 , 2 )
Inhibit interaction with:
PPP1CC (human) ( 2 )

References 

1

Mino T, Takeuchi O (2017) NSD3 keeps IRF3 active. J Exp Med 214, 3475-3476
29158375   Curated Info

2

Wang C, et al. (2017) The methyltransferase NSD3 promotes antiviral innate immunity via direct lysine methylation of IRF3. J Exp Med 214, 3597-3610
29101251   Curated Info